2021
Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients
PEHALOVÁ, Lucie, Denisa KREJČÍ, Jana HALÁMKOVÁ, Lenka ŠMARDOVÁ, Lenka ŠNAJDROVÁ et. al.Základní údaje
Originální název
Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients
Autoři
PEHALOVÁ, Lucie (203 Česká republika, garant, domácí), Denisa KREJČÍ (203 Česká republika, domácí), Jana HALÁMKOVÁ (203 Česká republika, domácí), Lenka ŠMARDOVÁ (203 Česká republika, domácí), Lenka ŠNAJDROVÁ (203 Česká republika, domácí) a Ladislav DUŠEK (203 Česká republika, domácí)
Vydání
Cancer Epidemiology, Oxford, Elsevier, 2021, 1877-7821
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30204 Oncology
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.890
Kód RIV
RIV/00216224:14110/21:00121472
Organizační jednotka
Lékařská fakulta
UT WoS
000652749700004
Klíčová slova anglicky
Haematological malignancies; Subsequent primary tumour; Time trends; Standardised incidence ratio; Survival
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 15. 6. 2021 13:17, Mgr. Tereza Miškechová
Anotace
V originále
Background Numbers of patients who develop subsequent primary tumours have markedly increased recently. This study aimed to carry out a comprehensive analysis documenting the risk of incidence of subsequent haematological malignancies. Methods The Czech National Cancer Registry was the main data source, containing records of 126,822 haematological malignancies diagnosed in the period 1977–2016. Subsequent haematological malignancies were identified according to IACR rules. Joinpoint regression was employed to assess the time trends. The risk of development of subsequent haematological malignancy was evaluated by the standardised incidence ratio. The Kaplan–Meier curves were used to assess the differences in survival. Results Age-standardised incidence of subsequent haematological malignancies increased from 0.5 in 1977 to 9.1 in 2016. In 1992, there was a significant change in the trend: a sharp increase by 7.7 % annually was revealed thereafter. The risk of development of a haematological malignancy was approximately 1.5 times higher in persons with history of any cancer than in the general Czech population. Patients with haematological malignancies – mainly myelodysplastic syndromes, polycythaemia vera and non-Hodgkin lymphoma – were shown to be at the highest risk of developing a subsequent haematological malignancy. While the median survival following a first haematological malignancy was 2.3 years, it was only 1.1 years for subsequent haematological malignancies (p < 0.001). Conclusions Our study identified the highest-risk diagnoses in terms of development of subsequent haematological malignancy. The results might be useful to set up correctly follow-up procedures from which cancer patients could benefit.